Shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) have been given an average recommendation of “Buy” by the eleven analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $30.00.

A number of brokerages recently weighed in on ITCI. ValuEngine cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th. BidaskClub cut shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Friday, June 22nd. Royal Bank of Canada restated a “buy” rating and set a $35.00 price objective on shares of Intra-Cellular Therapies in a research note on Friday, August 3rd. Canaccord Genuity set a $31.00 price objective on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a research note on Wednesday, June 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $28.00 price objective on shares of Intra-Cellular Therapies in a research note on Monday, July 23rd.

A number of institutional investors have recently modified their holdings of ITCI. NumerixS Investment Technologies Inc bought a new stake in Intra-Cellular Therapies in the second quarter worth about $167,000. Cubist Systematic Strategies LLC raised its position in Intra-Cellular Therapies by 53.0% in the second quarter. Cubist Systematic Strategies LLC now owns 9,641 shares of the biopharmaceutical company’s stock worth $170,000 after acquiring an additional 3,339 shares in the last quarter. Atlantic Trust Group LLC bought a new stake in Intra-Cellular Therapies in the first quarter worth about $215,000. State Board of Administration of Florida Retirement System raised its position in Intra-Cellular Therapies by 19.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 20,462 shares of the biopharmaceutical company’s stock worth $362,000 after acquiring an additional 3,400 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new stake in Intra-Cellular Therapies in the first quarter worth about $363,000. Hedge funds and other institutional investors own 68.81% of the company’s stock.

Shares of NASDAQ ITCI traded down $0.09 during midday trading on Friday, reaching $20.89. 211,467 shares of the company traded hands, compared to its average volume of 190,933. Intra-Cellular Therapies has a 52 week low of $13.93 and a 52 week high of $25.82. The stock has a market cap of $1.15 billion, a P/E ratio of -9.85 and a beta of 0.84.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. Intra-Cellular Therapies had a negative net margin of 39,745.53% and a negative return on equity of 31.73%. analysts expect that Intra-Cellular Therapies will post -3.15 EPS for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

See Also: Average Daily Trade Volume – What You Need to Know

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.